Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Kymr - The Untold Story

Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data

Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while preparing to share additional data from its IRF5 program later this year. Speaking at an RBC Capital Mar

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday released clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its oral STAT6 degrader medicine.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

4 Downgraded Stocks You'll Want to Sell or Avoid Right Now

With the growing odds of the economy tipping into a recession due to an aggressive monetary policy tightening to tame the sky-high inflation, it could be difficult for fundamentally weak stocks to stay afloat. Invesco (IVZ), Kymera (KYMR), Mogo (MOGO), and Sana Biotechnology (SANA) have been recently downgraded by our…

Kymera Therapeutics Commences Initial-Stage Oncology Trials

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Kymera Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter.

Why Kymera Therapeutics Shares Are Falling Today

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ:KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). In…

inkl

Read news from The Economist, FT, and more,
with one subscription

Kymera Therapeutics: Q1 Earnings Insights

Kymera Therapeutics: Q1 Earnings Insights

Kymera Therapeutics (NASDAQ:KYMR) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Analyst Ratings for Kymera Therapeutics

Analyst Ratings for Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET

Kymera Therapeutics Q1 2022 Earnings Conference Call On May 3, 2022 At 08:00 AM ET

Kymera Therapeutics (NASDAQ:KYMR) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Kymera Therapeutics (KYMR) Conference Call Follow this link to access the live webcast.

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474

JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ:KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says that the Company is "relatively insulated from downside pressure versus the benchmark from a healthy balance sheet." At the end of 2021, Kymera held approximately $567.6 million in cash, cash equivalents, and investments.…

1

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Kymera rapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Monetary Policy

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play